151. Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide enhances hippocampal long-term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation
- Author
-
Tao Ma, Xueyan Zhou, Wenzhong Yang, Stephen M. Day, and Sarah E. Ewin
- Subjects
0301 basic medicine ,Agonist ,Male ,endocrine system ,medicine.drug_class ,Cognitive Neuroscience ,Blotting, Western ,Long-Term Potentiation ,Morris water navigation task ,Hippocampal formation ,Mechanistic Target of Rapamycin Complex 1 ,Protein Serine-Threonine Kinases ,Hippocampus ,Glucagon-Like Peptide-1 Receptor ,Article ,Tissue Culture Techniques ,03 medical and health sciences ,0302 clinical medicine ,Glucagon-Like Peptide 1 ,medicine ,Glucose homeostasis ,Animals ,Phosphorylation ,Receptor ,Maze Learning ,Spatial Memory ,Chemistry ,digestive, oral, and skin physiology ,Long-term potentiation ,Mice, Inbred C57BL ,030104 developmental biology ,Shal Potassium Channels ,Synaptic plasticity ,Female ,Peptides ,Neuroscience ,030217 neurology & neurosurgery ,hormones, hormone substitutes, and hormone antagonists ,Central Nervous System Agents - Abstract
Glucagon-like peptide-1 (GLP-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion. Its natural cleavage product GLP-1 (9-36), used to be considered a "bio-inactive" metabolite mainly because of its lack of insulinotropic effects and low affinity for GLP-1 receptors, possesses unique properties such as anti-oxidant and cardiovascular protection. Little is known about the role of GLP-1 (9-36) in central nervous system. Here we report that chronic, systemic application of GLP-1 (9-36) in adult mice facilitated both the induction and maintenance phases of hippocampal long-term potentiation (LTP), a major form of synaptic plasticity. In contrast, spatial learning and memory, as assessed by the Morris water maze test, was not altered by GLP-1 (9-36) administration. At the molecular level, GLP-1 (9-36) reduced protein levels of the potassium channel Kv4.2 in hippocampus, which is linked to elevated dendritic membrane excitability. Moreover, GLP-1(9-36) treatment inhibited phosphorylation of mRNA translational factor eEF2, which is associated with increased capacity for de novo protein synthesis. Finally, we showed that the LTP-enhancing effects by GLP-1 (9-36) treatment in vivo were blunted by application of exendin(9-39)amide [EX(9-39)], the GLP-1 receptor (GLP-1R) antagonist, suggesting its role as a GLP-1R agonist. These findings demonstrate that GLP-1 (9-36), which was considered a "bio-inactive" peptide, clearly exerts physiological effects on neuronal plasticity in the hippocampus, a brain region critical for learning and memory.
- Published
- 2017